Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.

Cells · 2019 · PMC6406403 · PMID 30795553

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

In contrast to NVP-BGJ398, the growth inhibition of NRH-LS1 and LPS510 was strong after withdrawal of LY2874455, although it was quite significant with LPS510 cells, especially at the highest doses ( Figure 3 A–D).

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.